{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2015-D-1211\" and posted_year = 2015 sorted by posted_date descending", "rows": [["FDA-2015-D-1211-0098", "FDA", "FDA-2015-D-1211", "Revised Recommendations for Reducing the Risk of Human  Immunodeficiency Virus Transmission by Blood and Blood Products;\nGuidance for Industry; Availability,", "Notice", "Notice of Availability", "2015-12-23T05:00:00Z", 2015, 12, "2015-12-23T05:00:00Z", null, "2023-02-28T14:29:06Z", "2015-32250", 0, 0, "0900006481dca583"], ["FDA-2015-D-1211-0099", "FDA", "FDA-2015-D-1211", "Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Other", "Guidance", "2015-12-23T05:00:00Z", 2015, 12, "2015-12-23T05:00:00Z", null, "2023-02-28T14:36:21Z", null, 0, 0, "0900006481dcd33a"], ["FDA-2015-D-1211-0028", "FDA", "FDA-2015-D-1211", "Ref. 25 Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P, Viral hepatitis and HIV co-infection re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:47Z", null, 0, 0, "0900006481ae6b04"], ["FDA-2015-D-1211-0036", "FDA", "FDA-2015-D-1211", "Ref. 33 Custer B, Sheon N, Siedle-Khan B, Pollack L, Spencer B, Bialkowski W, D\u2019Andrea P, Sullivan M, Glynn S, Williams A, NHLBI Recipient Epidemiology and Donor Evaluation-III (REDS-III), Noncompliance with the men who have sex with me re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:20Z", null, 0, 0, "0900006481ae6c63"], ["FDA-2015-D-1211-0040", "FDA", "FDA-2015-D-1211", "Ref. 37 Lucky TTA, Seed CR, Waller D, Lee JF, McDonald A, Wand H, Wroth S, Shuttleworth G, Keller AJ, Pink J, Wilson DP, Understanding noncompliance with selective donor deferral criteria for high-risk behaviors in Australian blood donors re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:48Z", null, 0, 0, "0900006481ae6c67"], ["FDA-2015-D-1211-0043", "FDA", "FDA-2015-D-1211", "Ref. 40 Weller S, Davis-Beaty K, Condom effectiveness in reducing heterosexual HIV transmission re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:54:05Z", null, 0, 0, "0900006481ae6c6a"], ["FDA-2015-D-1211-0033", "FDA", "FDA-2015-D-1211", "Ref. 30 FDA workshop on Quarantine Release Errors in Blood Establishments, September 2011 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:01Z", null, 0, 0, "0900006481ae6d98"], ["FDA-2015-D-1211-0034", "FDA", "FDA-2015-D-1211", "Ref. 31 HHS Advisory Committee on Blood and Tissue Safety and Availability, Results from the Uniform Donor History Questionnaire, December 2013 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:09Z", null, 0, 0, "0900006481ae6d99"], ["FDA-2015-D-1211-0019", "FDA", "FDA-2015-D-1211", "Ref. 16 Klamroth R, Gr\u00f6ner A, Simon TL, Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:56Z", null, 0, 0, "0900006481ae6322"], ["FDA-2015-D-1211-0006", "FDA", "FDA-2015-D-1211", "Ref. 3 Stramer SL, Dodd RY, Transfusion-transmitted emerging infectious disease: 30 years of challenges and progress re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:22Z", null, 0, 0, "0900006481ae668d"], ["FDA-2015-D-1211-0009", "FDA", "FDA-2015-D-1211", "Ref. 6 Centers for Disease Control and Prevention, Epidemiologic Notes and Reports Possible Transfusion-Associated Acquired Immune Deficiency Syndrome re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:51Z", null, 0, 0, "0900006481ae6317"], ["FDA-2015-D-1211-0041", "FDA", "FDA-2015-D-1211", "Ref. 38 Mark KP, Janssen E, Milhausen RR, Infidelity in heterosexual couples: demographic, interpersonal, and personality-related predictors of extradyadic sex, Arch Sex Behav 2011 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:53Z", null, 0, 0, "0900006481ae6c68"], ["FDA-2015-D-1211-0027", "FDA", "FDA-2015-D-1211", "Ref. 24 United Kingdom Scientific, SaBTO Advisory Committee on the Safety of Blood, Tissues and Organs, Donor Selection Criteria Review, April 2011 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:41Z", null, 0, 0, "0900006481ae6aa3"], ["FDA-2015-D-1211-0029", "FDA", "FDA-2015-D-1211", "Ref. 26 Purcell DW, Johnson CH, Lansky A, Prejean J, Stein R, Denning P, Gaul Z, Weinstock H, Su J, Crepaz N, Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:52Z", null, 0, 0, "0900006481ae6b05"], ["FDA-2015-D-1211-0038", "FDA", "FDA-2015-D-1211", "Ref. 35 Offergeld R, et al, Sexual risk behavior and donor deferral in Europe, Vox Sanguinis 2014 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:34Z", null, 0, 0, "0900006481ae6c65"], ["FDA-2015-D-1211-0044", "FDA", "FDA-2015-D-1211", "Ref. 41 Smith DK, Herbst JH, Zhang X, Rose CE, Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the united states, J Acquir Immune Defic Syndr 2015 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:54:10Z", null, 0, 0, "0900006481ae6c6b"], ["FDA-2015-D-1211-0022", "FDA", "FDA-2015-D-1211", "Ref. 19 FDA Blood Products Advisory Committee Meeting, September 14, 2000 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:12Z", null, 0, 0, "0900006481ae6a9e"], ["FDA-2015-D-1211-0026", "FDA", "FDA-2015-D-1211", "Ref. 23 Kucirka LM1, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, Montgomery RA, Ros RL, Segev DL, Risk of window period HIV infection in high infectious risk donors re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:36Z", null, 0, 0, "0900006481ae6aa2"], ["FDA-2015-D-1211-0011", "FDA", "FDA-2015-D-1211", "Ref. 8 Van de Perre P, Clumeck N, Carael M, Nzabihimana E, Robert-Guroff M, De Mol P, Freyens P, Butzler JP, Gallo RC, Kanyamupira JB, Female prostitutes: a risk group for infection with human T-cell lymphotropic virus type III re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:05Z", null, 0, 0, "0900006481ae6319"], ["FDA-2015-D-1211-0012", "FDA", "FDA-2015-D-1211", "Ref. 9 FDA Memorandum Recommendations to decrease the Risk of Tramitting AIDS fro Blood donors re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:11Z", null, 0, 0, "0900006481ae631a"], ["FDA-2015-D-1211-0025", "FDA", "FDA-2015-D-1211", "Ref. 22 Federal Register Notice, \u201cRequest for Information (RFI) on Design of a Pilot Operational Study To Assess Alternative Blood Donor Deferral Criteria for Men Who Have Had Sex With Other Men re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:30Z", null, 0, 0, "0900006481ae6aa1"], ["FDA-2015-D-1211-0030", "FDA", "FDA-2015-D-1211", "Ref. 27  CDC, HIV Surveillance Report, 2012; vol 24. Published November 2014 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:59Z", null, 0, 0, "0900006481ae6b06"], ["FDA-2015-D-1211-0010", "FDA", "FDA-2015-D-1211", "Ref. 7 Ginzburg HM, Intravenous drug users and the acquired immune deficiency syndrome re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:58Z", null, 0, 0, "0900006481ae6318"], ["FDA-2015-D-1211-0003", "FDA", "FDA-2015-D-1211", "REFERENCE LIST re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:00Z", null, 0, 0, "0900006481ae6688"], ["FDA-2015-D-1211-0035", "FDA", "FDA-2015-D-1211", "Ref. 32 Custer B, Kessler D, Vahidnia F, Leparc G, Krysztof DE, Shaz B, Kamel H, Glynn S, Dodd RY, Stramer SL; NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II), Risk factors for retrovirus and hepatitis virus  re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:14Z", null, 0, 0, "0900006481ae6d9a"], ["FDA-2015-D-1211-0015", "FDA", "FDA-2015-D-1211", "Ref. 12 Perkins HA, Busch MP, Transfusion-associated infections: 50 years of relentless challenges and remarkable progress re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:33Z", null, 0, 0, "0900006481ae631d"], ["FDA-2015-D-1211-0031", "FDA", "FDA-2015-D-1211", "Ref. 28 CDC, Estimated HIV incidence in the United States, 2007\u20132010. HIV Surveillance Supplemental Report 2012; 17(No. 4). Published December 2012 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:46:05Z", null, 0, 0, "0900006481ae6b07"], ["FDA-2015-D-1211-0037", "FDA", "FDA-2015-D-1211", "Ref. 34 Benjamin RJ, et al, Deferral of males who had sex with other males, Vox Sanguinis 2011 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:27Z", null, 0, 0, "0900006481ae6c64"], ["FDA-2015-D-1211-0042", "FDA", "FDA-2015-D-1211", "Ref. 39 Stone E, Heagerty P, Vittinghoff E, Douglas JM Jr, Koblin BA, Mayer KH, Celum CL, Gross M, Woody GE, Marmor M, Seage GR III, Buchbinder SP, Correlates of condom failure in a sexually active cohort of men who have sex with men re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:59Z", null, 0, 0, "0900006481ae6c69"], ["FDA-2015-D-1211-0020", "FDA", "FDA-2015-D-1211", "Ref. 17 FDA Blood Products Advisory Committee Meeting, December 11-12, 1997 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:00Z", null, 0, 0, "0900006481ae6a9c"], ["FDA-2015-D-1211-0017", "FDA", "FDA-2015-D-1211", "Ref. 14 Ward JW, Grindon AJ, Feorino PM, Schable C, Parvin M, Allen JR, Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:44Z", null, 0, 0, "0900006481ae631f"], ["FDA-2015-D-1211-0014", "FDA", "FDA-2015-D-1211", "Ref. 11 Centers for Disease Control and Prevention, Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS): Report of Inter-Agency Recommendations re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:26Z", null, 0, 0, "0900006481ae631c"], ["FDA-2015-D-1211-0023", "FDA", "FDA-2015-D-1211", "Ref. 20 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era, 2006 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:18Z", null, 0, 0, "0900006481ae6a9f"], ["FDA-2015-D-1211-0045", "FDA", "FDA-2015-D-1211", "Ref. 42 FDA Blood Products Advisory Committee Meeting, December 2014 transcript re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:54:17Z", null, 0, 0, "0900006481ae6c6c"], ["FDA-2015-D-1211-0021", "FDA", "FDA-2015-D-1211", "Ref. 18 FDA Workshop on Donor Suitability, 1998 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:05Z", null, 0, 0, "0900006481ae6a9d"], ["FDA-2015-D-1211-0024", "FDA", "FDA-2015-D-1211", "Ref. 21 HHS Advisory Committee for blood safety and availability mtg, 2010 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:45:25Z", null, 0, 0, "0900006481ae6aa0"], ["FDA-2015-D-1211-0039", "FDA", "FDA-2015-D-1211", "Ref. 36 Seed CR, Kiely P, Law M, Keller AJ, No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T19:53:41Z", null, 0, 0, "0900006481ae6c66"], ["FDA-2015-D-1211-0016", "FDA", "FDA-2015-D-1211", "Ref. 13 Centers for Disease Control and Prevention, Update: Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma \u2013 United States re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:38Z", null, 0, 0, "0900006481ae631e"], ["FDA-2015-D-1211-0032", "FDA", "FDA-2015-D-1211", "Ref. 29 AABB on Quarantine Release Errors, White Paper 2013 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T18:46:10Z", null, 0, 0, "0900006481ae6b08"], ["FDA-2015-D-1211-0013", "FDA", "FDA-2015-D-1211", "Ref. 10 Leveton LB, Sox Jr HC, Stoto MA, eds, HIV and the blood supply: an analysis of crisis decisionmaking, Institute of Medicine, National Academy Press, Washington DC 1995 re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:17Z", null, 0, 0, "0900006481ae631b"], ["FDA-2015-D-1211-0018", "FDA", "FDA-2015-D-1211", "Ref. 15 Zou S, Stramer SL, Dodd RY, Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:17:50Z", null, 0, 0, "0900006481ae6320"], ["FDA-2015-D-1211-0004", "FDA", "FDA-2015-D-1211", "Reference. 1 FDA Memorandum to all Registered Blood Establishments re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:07Z", null, 0, 0, "0900006481ae668a"], ["FDA-2015-D-1211-0005", "FDA", "FDA-2015-D-1211", "Ref. 2 Epstein JS, Jaffe HW, Alter HJ, Klein HG, Blood system changes since recognition of transfusion-associated AIDS re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:15Z", null, 0, 0, "0900006481ae668b"], ["FDA-2015-D-1211-0007", "FDA", "FDA-2015-D-1211", "Ref. 4 Dubin C, Francis D, Closing the circle: a thirty-year retrospective on the AIDS/blood epidemic re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:28Z", null, 0, 0, "0900006481ae668e"], ["FDA-2015-D-1211-0008", "FDA", "FDA-2015-D-1211", "Ref. 5 Centers for Disease Control and Prevention, Epidemiologic Notes and Reports Pneumocystis carinii Pneumonia among Persons with Hemophilia A re Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Supporting & Related Material", "Background Material", "2015-05-18T04:00:00Z", 2015, 5, null, null, "2015-05-18T16:16:36Z", null, 0, 0, "0900006481ae668f"], ["FDA-2015-D-1211-0001", "FDA", "FDA-2015-D-1211", "Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2015-05-15T04:00:00Z", 2015, 5, "2015-05-15T04:00:00Z", "2015-07-15T03:59:59Z", "2023-04-27T01:00:42Z", "2015-11690", 0, 0, "0900006481ae2a95"], ["FDA-2015-D-1211-0002", "FDA", "FDA-2015-D-1211", "Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry", "Other", "Guidance", "2015-05-15T04:00:00Z", 2015, 5, "2015-05-15T04:00:00Z", null, "2023-02-28T14:36:50Z", null, 0, 0, "0900006481ae3a52"]], "truncated": false, "filtered_table_rows_count": 47, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2015-D-1211", "p1": "2015"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015", "results": [{"value": "FDA", "label": "FDA", "count": 47, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 43, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015", "results": [{"value": 2015, "label": 2015, "count": 47, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2015&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 1075.0825100112706, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}